Publication | Closed Access
A Phase I Study of an Anti-GD3 Monoclonal Antibody, KW-2871, in Patients with Metastatic Melanoma
28
Citations
19
References
2006
Year
An MTD of 40 mg/m2 without premedication was established for KW-2871, with urticaria being the most common side-effect and dose-limiting anaphylactoid infusion reactions.
| Year | Citations | |
|---|---|---|
Page 1
Page 1